Reaxys
PubChem
eMolecules
LabNetwork
Bioactivities (289)
SigmaAldrich
Reactions (3185)
Substances (1)
Structure
Targets (5)
Citations (3338)
N° of preparations All Preps | All Reactions
Structure/Compound Data Chemical Name: dibenzoyl peroxide
47 prep out of 3185 reactions.
Reaxys Registry Number: 984320
CAS Registry Number: 94-36-0 Type of Substance: isocyclic Molecular Formula: C14H10O4
Linear Structure Formula: [C6H5C(O)O]2 Molecular Weight: 242.231 InChI Key: OMPJBNCRMGITSC-UHFFFAOYSA-N
1
Available Data
Target
N° of ref.
Druglikeness
Bioactivity
Identification Physical Data (134) Spectra (81) Other Data (741)
Show Targets
3338
Highest Clinical Phase: Marketed
Synthesize | Hide Details Find similar Chemical Names and Synonyms dibenzoyl peroxide, Dibenzoyl peroxide, dibenzoylperoxide, BENZOYL PEROXIDE Druglikeness Bioactivity In vitro: Efficacy (256) Quantitative Results pX
Parameter
5.92
IC50
Value (qual)
Value (quant) 1200 10000
Unit nM
Action on Target
Target
Tissue/Organ
Cell
Bioassay In Vitro (others)
Dose
Effect
Reference (expand all/collapse all)
Antiproliferative
Patent: WO2007/89878 A...
Title/Abstract Full Text Show Details
ANGIOTECH PHARMACEUTICALS, INC.
Patent: WO2007/89878 A2, 2007 ; Title/Abstract Full Text Show Details
11
IC50
0.01
nM
smooth muscle cell
In Vitro (others)
Patent: WO2006/121518 ...
Title/Abstract Full Text Show Details
HUNTER, William, L.; TOLEIKIS, Philip, M.; GRAVETT, David, M.; MAITI, Arpita; LIGGINS, Richard T.; TAKACS-COX, Aniko; AVELAR, Rui; SIGNORE, Pierre, E.; LOSS, Troy, A. E.; HUTCHINSON, Anne; MCDONALD-JONES, Gaye; LAKHANI, Fara
Patent: WO2006/121518 A2, 2006 ; Title/Abstract Full Text Show Details
3.18
IC50
161
µg/mL
In Vitro (others)
Antiacne
Patent: WO2010/90845 A...
Title/Abstract Full Text Show Details
SIGNUM BIOSCIENCES, INC.; VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.
Patent: WO2010/90845 A1, 2010 ; Title/Abstract Full Text Show Details
3.18
IC50
161
µg/mL
In Vitro (others)
Antiacne
Patent: WO2010/90845 A...
Title/Abstract Full Text Show Details
Antiacne
Patent: WO2010/90845 A...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.
Patent: WO2010/90845 A1, 2010 ; Title/Abstract Full Text Show Details
3.18
IC50
161
µg/mL
In Vitro (others)
VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.
Patent: WO2010/90845 A1, 2010 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MBC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
pX
Parameter
2.99
MBC
Value (qual)
Value (quant)
Unit
250
µg/mL
Action on Target
Target
Tissue/Organ
Cell
Effect
Reference (expand all/collapse all)
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
Bioassay
Dose
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MBC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MBC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MBC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MBC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MBC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MBC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MBC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MBC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MBC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MBC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro
Antibiotic
Patent: WO2006/100495 ...
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MBC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MBC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MBC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MBC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MBC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MBC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MBC
62.5
µg/mL
(others)
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ;
Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MIC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MIC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MIC
125
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MIC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
2.99
MIC
250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MIC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MIC
15.6
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.49
MIC
7.8
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MIC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MIC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MIC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.89
MIC
31.25
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MIC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MIC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MIC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
4.19
MIC
15.6
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.59
MIC
62.5
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MBC
125 150
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MBC
125 250
µg/mL
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
3.29
MBC
125 250
µg/mL
In Vitro (others)
Antibiotic
Patent: WO2006/100495 ...
Title/Abstract Full Text Show Details
Archives of Biochemistry...
Title/Abstract Full Text View citing articles Show Details
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
6.3
IC50
=
500
nM
Inhibitor
protein kinase C:Wild
Gopalakrishna, Rayudu; Gundimeda, Usha; Anderson, Wayne B.; Colburn, Nancy H.; Slaga, Thomas J.
Archives of Biochemistry and Biophysics, 1999 , vol. 363, # 2 p. 246 - 258 Title/Abstract Full Text View citing articles Show Details
3.98
IC80
=
415
µM
Inhibitor
Ehrlich ascites carcinoma cell line
Journal of Natural Produ...
Title/Abstract Full Text Show Details
Ehrlich ascites carcinoma cell line
Journal of Natural Produ...
Title/Abstract Full Text Show Details
Journal of the European ...
Title/Abstract Full Text View citing articles Show Details
Woerdenbag; Moskal; Pras; Malingre; El-Feraly; Kampinga; Konings
Journal of Natural Products (Lloydia), 1993 , vol. 56, # 6 p. 849 - 856 Title/Abstract Full Text Show Details
3.47
IC50
=
337
µM
Inhibitor
Woerdenbag; Moskal; Pras; Malingre; El-Feraly; Kampinga; Konings
Journal of Natural Products (Lloydia), 1993 , vol. 56, # 6 p. 849 - 856 Title/Abstract Full Text Show Details
Activity
=
10.5
%
Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone
Journal of the European Academy of Dermatology and Venereology, 2007 , vol. 21, # 3 p. 320 - 325 Title/Abstract Full Text View citing articles Show Details
Activity
=
25.4
%
Journal of the European ...
Title/Abstract Full Text View citing articles Show Details
Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone
Journal of the European Academy of Dermatology and Venereology, 2007 , vol. 21, # 3 p. 320 - 325 Title/Abstract Full Text View citing articles Show Details
Activity
=
10.3
%
Journal of the European ...
Title/Abstract Full Text View citing articles Show Details
Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone
Journal of the European Academy of Dermatology and Venereology, 2007 , vol. 21, # 3 p. 320 - 325 Title/Abstract Full Text View citing articles Show Details
1
MIC
>
0.6
mg/mL
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
2.48
MIC
<=
0.8
mg/mL
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
3.08
MIC
<
0.2
mg/mL
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
MIC
>
0.2
mg/mL
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
2.78
MIC
<=
0.4
mg/mL
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
MIC
>
0.2
mg/mL
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
2.78
MIC
<=
0.4
mg/mL
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
3.08
MIC
<
0.2
mg/mL
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
MIC
>
0.4
mg/mL
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
2.61
MIC
<=
0.6
mg/mL
Antineoplastic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2012/232147 ...
Title/Abstract Full Text Show Details
Antimicrobial
Patent: US2010/184727 ...
Title/Abstract Full Text Show Details
Antimicrobial
Patent: US2010/184727 ...
Title/Abstract Full Text Show Details
Antimicrobial
Patent: US2010/184727 ...
Title/Abstract Full Text Show Details
Antimicrobial
Patent: US2010/184727 ...
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
1
Activity
NA
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
Activity
@
DIGNITY SCIENCES LIMITED
Patent: US2012/232147 A1, 2012 ; Title/Abstract Full Text Show Details
3.89
MIC
=
31.25
mg/L
SUMMIT (CAMBRIDGE) LIMITED
Patent: US2010/184727 A1, 2010 ; Title/Abstract Full Text Show Details
3.59
MBC
=
62.5
mg/L
SUMMIT (CAMBRIDGE) LIMITED
Patent: US2010/184727 A1, 2010 ; Title/Abstract Full Text Show Details
3.59
MBC
=
62.5
mg/L
SUMMIT (CAMBRIDGE) LIMITED
Patent: US2010/184727 A1, 2010 ; Title/Abstract Full Text Show Details
3.89
MIC
=
31.25
mg/L
Title/Abstract Full Text Show Details
SUMMIT (CAMBRIDGE) LIMITED
Patent: US2010/184727 A1, 2010 ; Title/Abstract Full Text Show Details
3.13
MBC90
=
1600
µg/mL
Antibiotic
Patent: WO2010/87964 A...
Title/Abstract Full Text Show Details
Antibiotic
Patent: WO2010/87964 A...
Title/Abstract Full Text Show Details
Antibiotic
Patent: WO2010/87964 A...
Title/Abstract Full Text Show Details
Antibiotic
Patent: WO2010/87964 A...
Title/Abstract Full Text Show Details
Antibiotic
Patent: WO2010/87964 A...
Title/Abstract Full Text Show Details
Antibiotic
Patent: WO2010/87964 A...
Title/Abstract Full Text Show Details
Antibiotic
Patent: WO2010/87964 A...
Title/Abstract Full Text Show Details
Antibiotic
Patent: WO2010/87964 A...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US2014/274879 ...
Title/Abstract Full Text Show Details
NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.
Patent: WO2010/87964 A2, 2010 ; Title/Abstract Full Text Show Details
3.74
MIC90
=
400
µg/mL
NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.
Patent: WO2010/87964 A2, 2010 ; Title/Abstract Full Text Show Details
3.08
MBC50
=
200
µg/mL
NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.
Patent: WO2010/87964 A2, 2010 ; Title/Abstract Full Text Show Details
4.64
MIC90
=
50
µg/mL
NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.
Patent: WO2010/87964 A2, 2010 ; Title/Abstract Full Text Show Details
3.69
MIC
<=
50 - 100
µg/ml
NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.
Patent: WO2010/87964 A2, 2010 ; Title/Abstract Full Text Show Details
3.69
MIC50
=
50
µg/mL
NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.
Patent: WO2010/87964 A2, 2010 ; Title/Abstract Full Text Show Details
4.04
MBC90
=
200
µg/mL
NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.
Patent: WO2010/87964 A2, 2010 ; Title/Abstract Full Text Show Details
3.38
MBC
100 400
µg/ml
NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.
Patent: WO2010/87964 A2, 2010 ; Title/Abstract Full Text Show Details
4.2
MIC
62.5
μM
BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS; Song, Peter I.; Armstrong, Cheryl; Ryu, Sunhyo; Park, Yoonkyung
Patent: US2014/274879 A1, 2014 ; Title/Abstract Full Text Show Details
4.2
MIC
62.5
μM
Antibiotic
BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS; Song, Peter I.; Armstrong, Cheryl; Ryu, Sunhyo; Park, Yoonkyung
Patent: US2014/274879 A1, 2014 ;
Patent: US2014/274879 ...
Title/Abstract Full Text Show Details
Title/Abstract Full Text Show Details
ZI
0-6
mm
Antibiotic
Patent: US9682031 B2, ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US9682031 B2, ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US9682031 B2, ...
Title/Abstract Full Text Show Details
Antibiotic
Patent: US9682031 B2, ...
Title/Abstract Full Text Show Details
Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior
Patent: US9682031 B2, 2017 ; Title/Abstract Full Text Show Details
ZI
12 - 17
mm
Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior
Patent: US9682031 B2, 2017 ; Title/Abstract Full Text Show Details
ZI
6 - 10
mm
Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior
Patent: US9682031 B2, 2017 ; Title/Abstract Full Text Show Details
ZI
6-8
mm
Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior
Patent: US9682031 B2, 2017 ; Title/Abstract Full Text Show Details
Qualitative Information 1 of 86
2 of 86
Biological material
human
Assay Description
Effect : |transport Bioassay : control: without title comp. hydrated nail clippings incubated with title comp. for 20 h; excess moisture removed; title comp. penetration activity measured as nail swelling and increase in nail weight
Results
title comp. did not significantly increase nail weight; table
Citation
Khengar; Jones; Turner; Forbes; Brown
Pharmaceutical Research, 2007 , vol. 24, # 12 p. 2207 - 2212 Title/Abstract Full Text View citing articles Show Details
Effect
Cytotoxic
Assay Description
3 of 86
Target : T1 cell line Bioassay : in Dulbecco's modified Eagle's medium with 10 percent FCS, HEPES and antibiotics; positive control: 0.5 ng/ml mezerein; 1E4 cells/ml; lowest conc. at which no sign. increase in foci compared to unexposed control determined; compared with Ames and SHE tests bovine papillomavirus DNA-carrying C3H/10T1/2 cell line; 200 cells from T1 passages 26-35 cocultured with 5E4 untransfected C3H/10T1/2 cells passages 16-19; incubated at 37 deg C for 72 hr; prediction of carcinogenicity; foci counted
Results
title comp. showed positive response; lowest transforming dose: 0.1 μmol/l
Citation
Kowalski; Assi; Wee; Madden Vera Genics
Environmental and Molecular Mutagenesis, 2001 , vol. 37, # 3 p. 231 - 240 Title/Abstract Full Text View citing articles Show Details
Effect
Antimicrobial
Biological material
Propionibacterium acnes
Assay Description
Bioassay : This example illustrates antimicrobial efficacy of topical benzoyl peroxide compositions in accordance with the present disclosure in skin during a three day study. Materials and Methods A split-face, randomized study of 24 patients was conducted. Patients were randomly divided into two groups of 12
4 of 86
5 of 86
6 of 86
7 of 86
8 of 86
Results
The 5% test compound in accordance with the present disclosure yielded a 0.2 log greater reduction in P. acnes than the 5% benzoyl peroxide gel and a 0.7 log greater reduction in P. acnes that the 5% benzoyl peroxide/1% clindamycin gel after 3 and 8
Citation
JR CHEM, LLC
Patent: US2006/204530 A1, 2006 ; Title/Abstract Full Text Show Details
Biological material
human
Assay Description
Effect : inflammatory lesion; effect on Bioassay : This example illustrates lesion reduction using topical 5% benzoyl peroxide compositions in accordance with the present disclosure. Materials and Methods Subjects were randomly assigned to receive 5% benzoyl peroxide compositions (meeting the U.S. Pharmacopoeia labeling requirements) in accordance with
Results
inflammatory lesion counts over treatment course: ~55.0% (4 week); ~35% (10week); figure given
Citation
JR CHEM, LLC
Patent: US2006/204530 A1, 2006 ; Title/Abstract Full Text Show Details
Biological material
human
Assay Description
Effect : non-inflammatory lesion; effect on Bioassay : This example illustrates lesion reduction using topical 5% benzoyl peroxide compositions in accordance with the present disclosure. Materials and Methods Subjects were randomly assigned to receive 5% benzoyl peroxide compositions (meeting the U.S. Pharmacopoeia labeling requirements) in accordance with
Results
non-inflammatory lesion counts over treatment course: 40.0% (4 week); ~38% (10week); figure given
Citation
JR CHEM, LLC
Patent: US2006/204530 A1, 2006 ; Title/Abstract Full Text Show Details
Target
Myeloperoxidase:Wild
Assay Description
Effect : |enzyme; examination of Bioassay : 20 mg in 0.2 ml acetone; applied topically to female mice CD-1; after killing MPO extraction from 22-mm diameter dorsal skin from polymorphonuclear leucocytes (PMNs) spectrophotometrically; MPO accumulation in mouse skin
Results
ability to elicit the accumulation of MPO as MPO activity: 0.04 +/- 0.01 (units/22 mm skin punch); 1 unit of MPO activity is equivalent to 8.6*106 murine PMNs
Citation
Trush; Egner; Kensler
Food and Chemical Toxicology, 1994 , vol. 32, # 2 p. 143 - 147 Title/Abstract Full Text Show Details
Effect
Antimicrobial
Biological material
Propionibacterium acnes
Results
reducing the number of P.acnes, figure 4 is given
Citation
KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert
Patent: WO2007/149868 A2, 2007 ; Title/Abstract Full Text Show Details
Effect
Antimicrobial
Assay Description
Effect : anti-microbial
9 of 86
10 of 86
11 of 86
Results
reducing the number of P.acnes, figure 4 is given
Citation
SK CHEMICALS CO., LTD.
Patent: WO2007/49868 A1, 2007 ; Title/Abstract Full Text Show Details
Effect
Antimicrobial
Assay Description
Effect : anti-microbial
Results
reducing the number of P.acnes, figure 4 is given
Citation
KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert
Patent: WO2007/149868 A2, 2007 ; Title/Abstract Full Text Show Details
Effect
Antimicrobial
Biological material
Propionibacterium acnes
Assay Description
Effect : anti-microbial
Results
reducing the number of P.acnes, figure 4 is given
Citation
KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert
Patent: WO2007/149868 A2, 2007 ; Title/Abstract Full Text Show Details
Effect
Antiacne
Assay Description
12 of 86
Results
title compound treatment resulted in a significant reduction in the acne lesion counts; title compound demonstrated a decrease in the total number of lesions observed on days 3(10%), 7(18%), 14(37%), 28(55%); title compound performed better in reducing
Citation
CONCERT, LLC
Patent: US2008/139518 A1, 2008 ; Title/Abstract Full Text Show Details
Effect
Sensitizing
Assay Description
13 of 86
Target : with Grade 2-3 facial acne of human Bioassay : B. Acne Clinical Trial Using Inventive FormulationFifteen panelists exhibiting Grade 2-3 facial acne were recruited for participation in this study. Panelists were randomized into three equal groups corresponding to the three different products they were using: Lotion 1, 2, and 3.Lotion 1 contained
Target : CBA mouse Bioassay : 6-12 wk old animals; housed under standard conitions with food and tap water ad libitum; international interlaboratory trial (5 participants) local lymph node assay; exposed on dorsum of both ears to 25 μl of 1 of 5 conc.; 5 d after the start of treatment injected i.v. with PSB cont. 20 μCi of <3H>methylthymidine (spec. act. 2 Ci/mmol); proliferative act. of draining auricular LNC measured
Results
elicited strong LLNA respnses in each participating laboratory; dpm: 658-9110 to 715-8595 (acetone: 27-463), SI: 14.6-24.4 to 16.1 to 26.5
Citation
Kimber; Hilton; Dearman; Gerberick; Ryan; Basketter; Lea; House; Ladics; Loveless; Hastings
Journal of Toxicology and Environmental Health, 1998 , vol. 53, # 7 p. 563 - 579 Title/Abstract Full Text Show Details
Effect
Mutagenic
Biological
Salmonella enterica serovar Typhimurium
material Assay Description
14 of 86
Citation
Dillon, Deborah; Combes, Robert; Zeiger, Errol
Mutagenesis, 1998 , vol. 13, # 1 p. 19 - 26 Title/Abstract Full Text View citing articles Show Details
Effect
Mutagenic
Assay Description
15 of 86
Dillon, Deborah; Combes, Robert; Zeiger, Errol
Mutagenesis, 1998 , vol. 13, # 1 p. 19 - 26 Title/Abstract Full Text View citing articles Show Details
Effect
Mutagenic
Dillon, Deborah; Combes, Robert; Zeiger, Errol
Mutagenesis, 1998 , vol. 13, # 1 p. 19 - 26 Title/Abstract Full Text View citing articles Show Details
Effect
Mutagenic
Target : Salmonella typhimurium TA97a Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix
Citation
Dillon, Deborah; Combes, Robert; Zeiger, Errol
Mutagenesis, 1998 , vol. 13, # 1 p. 19 - 26 Title/Abstract Full Text View citing articles Show Details
Effect
Cytotoxic
Biological material
human HaCat
Assay Description
18 of 86
Target : Salmonella typhimurium TA104 Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix
Citation
Assay Description
17 of 86
Target : Salmonella typhimurium TA102 Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix
Citation
Assay Description
16 of 86
Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix
Bioassay : control: 1 percent ethanol cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiotics at 37 deg C; 5 percent CO2; seeded 75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h; Neutral red assay; neutral red dye uptake as measure of cell viablity
Results
min. cytotoxicity at doses from 100 to 200 μmol/l ( cell viability ca. 99 percent); significant cytotoxicity at doses 250 and 300 μmol/l (cell viability 70 and 50 percent resp.) (fig.)
Citation
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester
Toxicology, 2001 , vol. 165, # 2-3 p. 225 - 234 Title/Abstract Full Text View citing articles Show Details
Effect
Genotoxic
Biological material
human HaCat
Assay Description
Bioassay : control: untreated and 1 percent ethanol treated cells cells cult. in 75 cm2 plastic flask in DMEM medium with 10 percent FCS, antibiotics at 37 deg C; 5 percent CO2; seeded
75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h; flow cytometry, with propidium iodide (PI) staining; DNA fragmentat.
19 of 86
20 of 86
21 of 86
22 of 86
23 of 86
Results
little dose dependent DNA fragmentation from 1.1 to 4.9 percent
Citation
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester
Toxicology, 2001 , vol. 165, # 2-3 p. 225 - 234 Title/Abstract Full Text View citing articles Show Details
Target
cytokine:Wild
Biological material
human HaCat
Assay Description
Effect : cytokines; expression of Bioassay : EPh: electrophoresis; internal control: β-actin cells cult. in 75 cm2 pl. flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 2E5 cell/cm2 in 12well plates for 24 h; confl. 90 percent; treat. for 6, 12, 24 h; total RNA extr.; rev. transcrip.; IL-1α, IL-8, β-actin PCR ampl.; EPh
Results
dose-dependent increase of IL-1α mRNA steady state levels; more significant after 6 h incubation 2.8, 3.8 and 5-fold at doses 50, 100 and 200 μmol/l resp.; no effect on IL-8 mRNA level (fig.)
Citation
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester
Toxicology, 2001 , vol. 165, # 2-3 p. 225 - 234 Title/Abstract Full Text View citing articles Show Details
Target
NF-kappaB:Wild
Biological material
human HaCat
Assay Description
Effect : NF-κB activation Bioassay : pGL3-4κB-Luc and pRL-TK plasmids; dual-luciferase reporter assay system; positive control: TNFα (5 and 20 ng/ml) treatment cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 2E5 cell/cm2 in 12-well plates for 24 h; confl. 90 percent; co-transfect.; incub. for 18 h; treat. for 24 h; cell lysis 12 h after tr.; luciferase act.
Citation
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester
Toxicology, 2001 , vol. 165, # 2-3 p. 225 - 234 Title/Abstract Full Text View citing articles Show Details
Biological material
human HaCat
Assay Description
Effect : |metabolic Bioassay : GSH: reduced glutathione; GSSG: oxidized glutathione; control: untreated and 1 percent ethanol treated cells cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h and from 30 min to 6 h at dose 300 μmol/l; HPLC; GSH, GSSG, vit. E lev.
Results
dose-dependent decrease of vit. E and GSH levels from 8 to 4 pmol/E6 cells and from 10.7 to 0.4 nmol/E6 cells; increase of GSSG/GSH ratio from 2.3 to 90.4 percent; time course study: 50 percent decrease of vit. E and GSH level at 30 min and 6 h resp.
Citation
Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester
Toxicology, 2001 , vol. 165, # 2-3 p. 225 - 234 Title/Abstract Full Text View citing articles Show Details
Results
no mutagenicity in test on Salmonella typhimurium TA 98 and TA 100
Citation
Yamaguchi; Yamashita
Agricultural and Biological Chemistry, 1980 , vol. 44, # 7 p. 1675 - 1678 Title/Abstract Full Text View citing articles Show Details
Effect
Keratolytic
Biological material Assay Description
24 of 86
mean SC removed (μg/cm2) after 3 h of treatment: 1.46 (control: 1.01), after 6 h: 1.64 (control: 1.31); mean TEWL taken 5 times over 30 min at 3 h after stripping: 30.08 and at 6 h: 28.76 (control: 9.68 and 11.65)
Citation
Waller; Dreher; Behnam; Ford; Lee; Tiet; Weinstein; Maibach
Skin Pharmacology and Physiology, 2006 , vol. 19, # 5 p. 283 - 289 Title/Abstract Full Text View citing articles Show Details
Effect
Mutagenic
27 of 86
Martinez, A.; Urios, A.; Blanco, M.
Mutation research, 2000 , vol. 467, # 1 p. 41 - 53 Title/Abstract Full Text Show Details
Effect
Mutagenic
Target : Escherichia coli IC203 Bioassay : WP2 uvrA/pKM101 bacterial strain deficient in OxyR in vitro; plate incorporation assay; Difco agar; minimal ET4 plates; 37 deg C; 2 d; number of revertants per plates counted
Citation
Martinez, A.; Urios, A.; Blanco, M.
Mutation research, 2000 , vol. 467, # 1 p. 41 - 53 Title/Abstract Full Text Show Details
Assay Description
Effect : |DNA; examination of Target : supercoiled pBR 322 DNA (form I, MW of 2.9E6 Da, 4365 bp) Bioassay : Reactivity of benzoyloxyl versus tert-butoxyl radicals was assessed by comparison with tert-butyl perbenzoate; ssb=single-strand breaks The title comp. in water with DNA in KH2PO4 buffer (pH 7.4) were irradiated (UV, λ=300 nm); 0 deg C; 2 min or 10 min; the DNA-cleaving activity of the title comp. assessed; gel electrophoresis analysis
Results
The blank value of open circular DNA: without irrad. 0.04 ssb, after 10 min irrad. 0.06 ssb per DNA molecule 4E3 bp; irradiation with the title comp.: 0.06 ssb (2 min) and 0.09 ssb (10 min) per DNA molecule; the moderate activity of title comp.
Citation
Adam, Waldemar; Grimm, Guenther N.; Saha-Moeller, Chantu R.; Dall'Acqua, Francesco; Miolo, Gorgia; Vedaldi, Daniela
Chemical Research in Toxicology, 1998 , vol. 11, # 9 p. 1089 - 1097 Title/Abstract Full Text View citing articles Show Details
Effect
Antibiotic
Assay Description
28 of 86
Target : Escherichia coli IC188 Bioassay : parent WP2 uvrA/pKM101 bacterial strain in vitro; plate incorporation assay; Difco agar; minimal ET4 plates; 37 deg C; 2 d; number of revertants per plates counted
Citation
Assay Description
26 of 86
Bioassay : SC: stratum corneum randomized, blinded and placebo-controlled study; TEWL measurements taken using closed-chamber evaporimeter; 25 tape stripping and protein assay
Results
Assay Description
25 of 86
human
Target : ATC 25577 of Propionibacterium avidum Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 25.83 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Target : ATCC 12600 of Staphylococcus aureus
Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
29 of 86
Results
title compound resulted in a 11.99 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
30 of 86
Results
title compound resulted in a 12.20 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
31 of 86
title compound resulted in a 11.68 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : ATCC 12602 of Staphylococcus aureus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 12.73 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
33 of 86
Target : ATCC 12601 of Staphylococcus aureus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
Assay Description
32 of 86
Target : ATCC 12600-U of Staphylococcus aureus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Target : ATCC 12604 of Staphylococcus aureus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 12.52 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
34 of 86
Results
title compound resulted in a 12.20 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
35 of 86
title compound resulted in a 11.68 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : ATCC 12607 of Staphylococcus aureus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 12.31 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
37 of 86
Target : ATCC 12606 of Staphylococcus aureus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
Assay Description
36 of 86
Target : ATCC 12605 of Staphylococcus aureus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Target : ATCC 25923 of Staphylococcus aureus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 10.86 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Target : ATCC 27836 of Staphylococcus warneri Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 12.04 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
38 of 86
Effect Assay Description
39 of 86
title compound resulted in a 12.46 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
title compound resulted in a 11.83 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : ATCC 27848 of Staphylococcus simulans Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 9.94 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
42 of 86
Target : ATCC 27848 of Staphylococcus hominis Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
Assay Description
41 of 86
Target : ATCC 27848 of Staphylococcus capitis Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
Assay Description
40 of 86
Antibiotic
Target : ATCC 29212 of Enterococcus faecalis Bioassay : Example 10 - activity against E. faecalisThe activities of BP, TBHQ and combinations of the two were tested against E. faecalis ATCC 29212, using MIC, MBC and (S)DDA assays as described above.For the (S)DDA assays, 200 μg of each compound was loaded onto each disc. The solvents used were DMSO for
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Target : ATCC 29213 of Staphylococcus aureus Bioassay : Example 1 - activity against S. aureus -MIC, MBC & (S)DDA assaysThe following experiments all used S. aureus ATCC 29213 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using the test compound benzoyl peroxide (BP) and a range of different benzoquinones and hydroquinones.
Results
title compound resulted in a 11.03 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
43 of 86
Effect Assay Description
44 of 86
125 μg/ml of title compound resulted in a 3.67E4-7.63E5 CFU/ml t=0-1.0 wherein time to kill was >1 h
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
mixture of BP and TBHQ showed reduction in microbial activity greater (after 24 hours) than that obtained using title compound alone
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : ATCC 29970 of Staphylococcus haemolyticus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 11.10 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
47 of 86
Target : ATCC 29213 of Staphylococcus aureus Bioassay : Example 4 - activity against S aureus - MTTK assaysSamples containing BP, TBHQ and BP/TBHQ mixtures were also subjected to MTTK assays as described above, using S. aureus ATCC 29213 as the test organism The BP was dissolved in DMSO and the TBHQ in ethanolThe results, after 24 hours, are shown in Table
Results
Assay Description
46 of 86
Target : ATCC 29213 of Staphylococcus aureus Bioassay : Example 3 - activity against S. aureus - TTK assaysTTK assays were then conducted, as described above, on samples of BP, TBHQ and a BP/TBHQ mixture, using S. aureus ATCC 29213 as the test organism. The solvents used were DMSO for the BP and ethanol for the TBHQ. The results are shown in Table 3. cfu
Results
Assay Description
45 of 86
Antibiotic
Target : ATCC 29971 of Staphylococcus xylosus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 10.99 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Target : ATCC 29974 of Staphylococcus cohnii Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 11.51 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ;
Title/Abstract Full Text Show Details
48 of 86
Effect Assay Description
49 of 86
title compound resulted in a 21.56 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
title compound resulted in a 10.17 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : CPHL EMRSA 16 of Staphylococcus aureus methicillin (Met)/β-lactams resistant Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 10.80 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
52 of 86
Target : CPHL EMRSA 15 of Staphylococcus aureus methicillin (Met)/β-lactams resistant Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
Assay Description
51 of 86
Target : ATCC 33753 of Staphylococcus auricularis Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
Assay Description
50 of 86
Antibiotic
Target : CPHL EMRSA 17 of Staphylococcus simulans methicillin (Met)/β-lactams resistant Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 11.74 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Results
Target : CPHL GISA HO41340156 of Staphylococcus aureus vancomycin (Van)/teicoplanin (Tec)-resistant Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above title compound resulted in a 12.16 mm disc diffusion assay (DDA)
53 of 86
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
54 of 86
Results
title compound resulted in a 10.90 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
55 of 86
title compound resulted in a 11.64 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : NCTC 11047 of Staphylococcus epidermidis Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
title compound resulted in a 10.65 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
57 of 86
Target : CPHL VISA Mu50 of Staphylococcus aureus vancomycin (Van)-resistant Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Results
Assay Description
56 of 86
Target : CPHL VISA Mu3 of Staphylococcus aureus vancomycin (Van)-resistant Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
Target : NCTC 11865 of Propionibacterium granulosum Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 24.19 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Target : NCTC 7292 of Staphylococcus saprophyticus Bioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above
58 of 86
Results
title compound resulted in a 11.38 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
59 of 86
Results
title compound resulted in a 24.25 mm disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
60 of 86
title compound resulted in 19.25 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : PRP-002 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 25.69 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
62 of 86
Target : NCTC 737 of Propionibacterium acnes Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
Assay Description
61 of 86
Target : NCTC 737 of Propionibacterium acnes Bioassay : Example 6 - activity against P. acnes -MIC, MBC & (S)DDA assaysThe following experiments all used P. acnes NCTC 737 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using BP and a range of different benzoquinones and hydroquinones. Supplemented DDA assays, in the presence
Target : PRP-003 of Propionibacterium acnes tetracycline (Tet)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 25.69 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay
63 of 86
Description
Target : PRP-004 of Propionibacterium acnes tetracycline (Tet)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 31.17 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
64 of 86
Results
title compound resulted in 22.95 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
65 of 86
Target : PRP-007 of Propionibacterium acnes clindamycin (Clin)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 23.88 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
66 of 86
Target : PRP-005 of Propionibacterium granulosum macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Target : PRP-008 of Propionibacterium acnes clindamycin (Clin)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 27.80 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Target : PRP-010 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 30.39 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
67 of 86
Effect Assay Description
68 of 86
title compound resulted in 23.28 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
title compound resulted in 24.11 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : PRP-026 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 26.52 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
71 of 86
Target : PRP-023 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
Assay Description
70 of 86
Target : PRP-017 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
Assay Description
69 of 86
Antibiotic
Target : PRP-043 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 22.48 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Target : PRP-044 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 29.31 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
72 of 86
Effect Assay Description
73 of 86
title compound resulted in 24.36 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
title compound resulted in 29.72 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Target : PRP-055 of Propionibacterium granulosum Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 21.52 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
76 of 86
Target : PRP-053 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
Assay Description
75 of 86
Target : PRP-046 of Propionibacterium acnes Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
Assay Description
74 of 86
Antibiotic
Target : PRP-059 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 23.49 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
Results
Target : PRP-068 of Propionibacterium acnes erythromycin (Ery)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above title compound resulted in 28.79 mm in disc diffusion assay (DDA)
77 of 86
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
78 of 86
Results
title compound resulted in 25.73 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Effect
Antibiotic
Assay Description
79 of 86
80 of 86
81 of 86
Target : PRP-101 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Target : PRP-102 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamide-streptogramin (MLS)-resistant Bioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above
Results
title compound resulted in 29.62 mm in disc diffusion assay (DDA)
Citation
EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott
Patent: WO2006/100495 A1, 2006 ; Title/Abstract Full Text Show Details
Target
enzyme:Wild
Assay Description
Effect : |enzyme; inhib. of Bioassay : protein kinase C (PKC) activity measured after 24 h of exposure; immunoblot analysis cultured cells from adult breast skin were grown and maintained in serum-free medium with var. Ca(2+) conc.; cells treated with soln. of title comp. in acetone; cell proliferation, phorbol ester-induced differentiation determined using <3H>-thymidine
Results
title comp. does not downregulate subcellular levels of PKC activity after 24 h expos.; does not significantly antagonize phorbol ester-induced inhib. of prolife. and differentiation; inhibits both human and murine PKC activity in vitro
Citation
Matsui; Mintz; DeLeo
Skin Pharmacology, 1995 , vol. 8, # 3 p. 130 - 138 Title/Abstract Full Text View citing articles Show Details
Target
enzyme:Wild
Assay Description
Effect : |enzyme; examination of Bioassay : in PBS; compared to untreated control in vitro; cells maintained with or without pretreatment CDNB (chlorodinitrobenzene) for 1 h; treated title comp.; exposed; measured cellular reduced glutathione (GSH) spectrophotometrically at 412 nm according to Anderson
Results
title comp. reduced intracellular GSH level at conc. 0.5 mM and higher (75, 54, 31, 31 percent at 0.5, 1.0, 1.5, 2.0 mM); pretreatment with CDNB lowered intracellular level of GSH to 15 percent of control cells and enhanced their subsequent sensitivity
Citation
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau
Toxicology, 1996 , vol. 106, # 1-3 p. 187 - 196 Title/Abstract Full Text View citing articles Show Details
Effect
Cytotoxic
Assay Description
Target : human keratinocyte cell line, RHEK-1 Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed; assessed cell proliferation using quantitative determination of DNA with the fluorochrome, bisbenzimidazole
82 of 86
Results
time required for the DNA content to double, h: 20 (control), 23, 24, 38, 48 at 0.02, 0.04, 0.06, 0.08 mM title comp., respect; after 7 d of exposure cell population, percent of control: 86, 76, 69, 61 at 0.02, 0.04, 0.06, 0.08 mM title comp., respect.
Citation
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau
Toxicology, 1996 , vol. 106, # 1-3 p. 187 - 196 Title/Abstract Full Text View citing articles Show Details
Effect
Cytotoxic
Assay Description
83 of 86
Results
at all tested conditions title comp. resulted in an increase in multinucleation and in extensive vacuolization; initially appeared vacuolization then spread throughout the cytoplasm
Citation
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau
Toxicology, 1996 , vol. 106, # 1-3 p. 187 - 196 Title/Abstract Full Text View citing articles Show Details
Effect
Cytotoxic
Assay Description
84 of 86
NR50 0.11 mmol/l
Citation
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau
Toxicology, 1996 , vol. 106, # 1-3 p. 187 - 196 Title/Abstract Full Text View citing articles Show Details
Effect
Cytotoxic
Target : human keratinocyte cell line, RHEK-1 Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; incubated cells with NR 3 h at 37 deg C; compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed for 1 h or 1 h followed by 48 h in title comp.-free medium; assessed cytotoxicity with neutral red (NR): uptake and lysosomal accumulation of supravital dye, NR
Results
title comp. caused irreversible damage for cells exposed 1-h at conc. > 0.15 mM; response cells to 1-h exposure followed by 48 h in title comp.-free medium 20 percent of control, while to only 1 h exposure - ca. 42 percent of control
Citation
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau
Toxicology, 1996 , vol. 106, # 1-3 p. 187 - 196 Title/Abstract Full Text View citing articles Show Details
Effect
Cytotoxic
Assay Description
86 of 86
Target : human keratinocyte cell line, RHEK-1 Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; incubated cells with NR 3 h at 37 deg C; calculated NR50 (reduced uptake NR by 50 percent); compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated exposure medium amended with varied conc. title comp.; exposed; assessed cytotoxicity with neutral red (NR), which is based on the uptake and lysosomal accumulation of supravital dye, NR
Results
Assay Description
85 of 86
Target : human keratinocyte cell line, RHEK-1 Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; compared to untreated control in vitro; cells incubated with growth medium 48-72 h; treated varied conc. title comp.; exposed: for 24 h, or 1 h followed by 48 h in title comp.-free medium; fixed; stained with Giemsa's solut.; examined miroscopically for cellular aberrations
Target : human keratinocyte cell line, RHEK-1 Bioassay : in PBS in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed; determined lactic acid dehydrogenase (LDH) release in supernatant using the CytoTox 96<R> Nonradiactive Cytotoxicity Assay Kit
Results
title comp. evoked signif. LDH release in supernatant at conc. 0.5 mM and higher; presented as graph
Citation
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau
Toxicology, 1996 , vol. 106, # 1-3 p. 187 - 196 Title/Abstract Full Text View citing articles Show Details
Effect
Cytotoxic
Assay Description
Target : human keratinocyte cell line, RHEK-1 Bioassay : in PBS; lipid peroxidation by conc. malondialdehyde and thiobarbituric acid reactive substances (TBARS); LDH reliase using CytoTox 96<R> Nonradioactive Cytotoxicity Assay Kit in vitro; cells maintained or not in vitamin E 24; treated title comp.; with or without 1 mM Fe(2+); exposed; estimated lipid peroxidation in supernatant and lactic acid dehydrogenase (LDH) release; compared to untreated control
Results
title comp. or Fe(2+) alone did not exhibit peroxidation; title comp.+Fe(2+) caused formation 0.7 or 2.3 nmol TBARS/mg cellular protein in cells maintained or not in vitamin E; LDH release: 71 percent and 74 percent without and with Fe(2+) and title
Citation
Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau
Toxicology, 1996 , vol. 106, # 1-3 p. 187 - 196 Title/Abstract Full Text View citing articles Show Details
In vivo: Animal Model (9) Quantitative Results pX
Parameter
Value (qual)
Value (quant)
Unit
Action on Target
Animal Model
Biological Species
Route of administration
MIC
80
mg/mL
transdermal administration
Dose
Dosing regimen
Effect
Reference (expand all/collapse all)
Antiinflammatory
Patent: WO2011/70170 A...
Title/Abstract Full Text Show Details
GALDERMA RESEARCH and DEVELOPMENT; BOUIX-PETER, Claire; PASCAL, Jean-Claude; RODEVILLE, Nicolas
Patent: WO2011/70170 A1, 2011 ; Title/Abstract Full Text Show Details
Qualitative Information 1 of 8
2 of 8
3 of 8
Biological material
Mus musculus
Assay Description
Effect : cutaneous iron levels; increase of Bioassay : control: untreated mice mice pretreated with 7,12-dimethylbenz(a)anthracene and iron-dextran; administered with title comp.; sacrificed at termination of tumor induction; dorsal skin removed; cutaneous iron levels were estimated by dipyridyl method
Results
non-tumor-bearing, tumor-bearing skin of mice treated with title comp. showed increase in cutaneous iron levels
Citation
Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad
Archives of Toxicology, 2004 , vol. 78, # 3 p. 139 - 146 Title/Abstract Full Text View citing articles Show Details
Biological material
Mus musculus
Assay Description
Effect : tumor-promoting Bioassay : mice pretreated with 7,12-dimethylbenz(a)anthracene in presence or absence of iron-dextran; administered with title comp.; carcinomas formed were counted and verified by histopathological examination
Results
tumor size of title comp.-treated mice was 62.3 mm2 and in iron-overloaded mice treated with title comp. was 74 mm2; fig.
Citation
Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad
Archives of Toxicology, 2004 , vol. 78, # 3 p. 139 - 146 Title/Abstract Full Text View citing articles Show Details
Biological material
Mus musculus
Assay Description
Effect : tumor-promoting Bioassay : DMBA: 7,12-dimethylbenz(a)anthracene mice pretreated with DMBA in presence or absence of iron-dextran; administered with title comp.; carcinomas formed were counted and verified by histopathological examination; percent of malignant conversion of benign papillomas into carcinomas was determined
Results
percent of incidence of carcinomas was 85 and 90 percent in normal and iron-overloaded mice treated with title comp., resp.; fig.
4 of 8
5 of 8
6 of 8
7 of 8
8 of 8
Citation
Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad
Archives of Toxicology, 2004 , vol. 78, # 3 p. 139 - 146 Title/Abstract Full Text View citing articles Show Details
Biological material
Mus musculus
Assay Description
Effect : tumor-promoting Bioassay : DMBA: 7,12-dimethylbenz(a)anthracene mice pretreated with DMBA in presence or absence of iron-dextran; mice administered with title comp.; mice sacrificed at termination of tumor induction; tissues removed; sections were stained with hematoxylin, eosin stains and examined microscopically
Results
epidermal ulceration was observed in tumor samples treated with iron and title comp.; table
Citation
Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad
Archives of Toxicology, 2004 , vol. 78, # 3 p. 139 - 146 Title/Abstract Full Text View citing articles Show Details
Assay Description
Effect : TPA-induced ear edema; reduction of Target : Balb/c ByJIc mouse Bioassay : Example 2 : Evaluation of the anti-inflammatory in ear oedema model on Balb/c miceThe study was carried out with 45 (5 par groups) female9 weeks aged Balb/c ByJIc mice.The Edema was induced by a single application of 20μl of TPA dissolved in acetone at 0.01%.The treatment was administrated by single
Results
2.5%, 5% and 10% title compound has a slight anti-inflammatory effect, reducing the TPA-induced ear edema by 16%, 24% and 40%, respectively; figure is given
Citation
GROSS, Denis; LOESCHE, Christian; PONCET, Michel; ABOU-CHACRA VERNET, Marie-line
Patent: WO2008/6888 A1, 2008 ; Title/Abstract Full Text Show Details
Biological material
human
Assay Description
Effect : lesions; reduction of Bioassay : Example 1: Clinical study results A clinical study for confirmation of efficacy was performed for a topical gel combining adapalene + benzoyl peroxide (BPO) . <n="13"/>This gel has the following formulation (expressed as % weight/total weight) :Adapalene 0.10%Benzoyl peroxide 2.50% Copolymer of acrylamide
Results
2.5% title compound treatment resulted in 15.4% degree of success, -43.6% number of inflammatory lesions, -36.4% number of non-inflammatory lesions, -35.6% total number of lesions, -13.0 number of inflammatory lesions, -16.0 number of non-inflammatory
Citation
GROSS, Denis; LOESCHE, Christian; PONCET, Michel; ABOU-CHACRA VERNET, Marie-line
Patent: WO2008/6888 A1, 2008 ; Title/Abstract Full Text Show Details
Biological material
Mus musculus
Assay Description
Effect : TPA-induced ear edema; reduction of Example 2 : Evaluation of the anti-inflammatory in ear oedema model on Balb/c miceThe study was carried out with 45 (5 par groups) female9 weeks aged Balb/c ByJIc mice.The Edema was induced by a single application of 20μl of TPA dissolved in acetone at 0.01%.The treatment was administrated by single
Results
2.5%, 5% and 10% title compound has a slight anti-inflammatory effect, reducing the TPA-induced ear edema by 16%, 24% and 40%, respectively; figure is given
Citation
GALDERMA RESEARCH and DEVELOPMENT
Patent: WO2008/6888 A1, 2008 ; Title/Abstract Full Text Show Details
Biological material
human
Assay Description
Effect : lesions; reduction of Example 1: Clinical study results A clinical study for confirmation of efficacy was performed for a topical gel combining adapalene + benzoyl peroxide (BPO) . <n="13"/>This gel has the following formulation (expressed as % weight/total weight) :Adapalene 0.10%Benzoyl peroxide 2.50% Copolymer of acrylamide
Results
2.5% title compound treatment resulted in 15.4% degree of success, -43.6% number of inflammatory lesions, -36.4% number of non-inflammatory lesions, -35.6% total number of lesions, -13.0 number of inflammatory lesions, -16.0 number of non-inflammatory
Citation
GALDERMA RESEARCH and DEVELOPMENT
Patent: WO2008/6888 A1, 2008 ; Title/Abstract Full Text Show Details
Metabolism (5) Quantitative Results pX
Parameter
Value (qual)
Value (quant)
Unit
Action on Target
Target
Tissue/Organ
Cell
Cell fraction
Substrate /Carried Molecule
Dose
1
Absorption
NA
Galderma Laboratories, L...
Full Text Show Details
Galderma Laboratories, L...
Full Text Show Details
Galderma Laboratories, L...
Full Text Show Details
Galderma Laboratories, L...
Full Text Show Details
Galderma Laboratories, L...
Full Text Show Details
Reference (expand all/collapse all)
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet Full Text Show Details
Absorption
45
%
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet Full Text Show Details
1
Absorption
NA
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet Full Text Show Details
1
Absorption
NA
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet Full Text Show Details
1
Absorption
NA
Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet Full Text Show Details
Pharmacokinetic (4) Quantitative Results pX
Parameter
Value (qual)
Value (quant)
Unit
Biological Species
Route of administration
Dose
Dosing regimen
Population
Reference (expand all/collapse all)
Ue (%)
45
%
Cercopithecidae
topical administration
Journal of the American ...
Title/Abstract Full Text Show Details
Nacht; Yeung; Beasley Jr.; Anjo; Maibach
Journal of the American Academy of Dermatology, 1981 , vol. 4, # 1 p. 31 - 37 Title/Abstract Full Text Show Details
Ue (%)
98
%
Cercopithecidae
intramuscular administration
Journal of the American ...
Title/Abstract Full Text Show Details
Nacht; Yeung; Beasley Jr.; Anjo; Maibach
Journal of the American Academy of Dermatology, 1981 , vol. 4, # 1 p. 31 - 37 Title/Abstract Full Text Show Details
Concentration
146
μg/g
Sprague Dawley rat
topical administration
50 mg
Single
Patent: WO2017/109761 ...
Title/Abstract Full Text Show Details
DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar
Patent: WO2017/109761 A1, 2017 ; Title/Abstract Full Text Show Details
Concentration
367
μg/g
Sprague Dawley rat
topical administration
50 mg
Single
Patent: WO2017/109761 ...
Title/Abstract Full Text Show Details
DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar
Patent: WO2017/109761 A1, 2017 ; Title/Abstract Full Text Show Details
Toxicity/Safety Pharmacology (15) Quantitative Results pX
Parameter
Value (qual)
Value (quant)
Unit
Action on Target
Target
Tissue/Organ
Cell
Bioassay
Dose
Effect
Reference (expand all/collapse all)
3.89
MIC
31.25
mg/L
Cell/tumor cell: proliferation/viability/growth
1.95000 mg/L
Patent: WO2007/141530 ...
Title/Abstract Full Text Show Details
mg/L
Cell/tumor cell: proliferation/viability/growth
1.95000 mg/L
Patent: WO2007/141530 ...
Title/Abstract Full Text Show Details
nM
fibroblast
Cell/tumor cell: proliferation/viability/growth
Antiproliferative
Patent: WO2007/89878 A...
Title/Abstract Full Text Show Details
1000
mg/kg
Material Safety Data She...
Full Text Show Details
250
mg/kg
Material Safety Data She...
Full Text Show Details
5700
mg/kg
Material Safety Data She...
Full Text Show Details
7710
mg/kg
Material Safety Data She...
Full Text Show Details
250
mg/kg
Material Safety Data She...
Full Text Show Details
5700
mg/kg
Material Safety Data She...
Full Text Show Details
ROACH, Alan George; GOLDSMITH, Paul
Patent: WO2007/141530 A2, 2007 ; Title/Abstract Full Text Show Details
Concentration
62.5
ROACH, Alan George; GOLDSMITH, Paul
Patent: WO2007/141530 A2, 2007 ; Title/Abstract Full Text Show Details
5.92
IC50
1200 10000
ANGIOTECH PHARMACEUTICALS, INC.
Patent: WO2007/89878 A2, 2007 ; Title/Abstract Full Text Show Details
LD50
Material Safety Data Sheet Full Text Show Details
LD50
=
Material Safety Data Sheet Full Text Show Details
LD50
=
Material Safety Data Sheet Full Text Show Details
LD50
=
Material Safety Data Sheet Full Text Show Details
LD50
Material Safety Data Sheet Full Text Show Details
LD50
Material Safety Data Sheet Full Text Show Details
LD50
=
1000
mg/kg
Material Safety Data She...
Full Text Show Details
7710
mg/kg
Material Safety Data She...
Full Text Show Details
64
mg/L
Material Safety Data Sheet Full Text Show Details
LD50
Material Safety Data Sheet Full Text Show Details
3.58
MIC
Cell/tumor cell: proliferation/viability/growth
Antibiotic
Marine Drugs, 2013 , vo...
Title/Abstract Full Text View citing articles Show Details
Cell/tumor cell: proliferation/viability/growth
Antibiotic
Marine Drugs, 2013 , vo...
Title/Abstract Full Text View citing articles Show Details
Cell/tumor cell: proliferation/viability/growth
Antibiotic
Marine Drugs, 2013 , vo...
Title/Abstract Full Text View citing articles Show Details
Cell/tumor cell: proliferation/viability/growth
Antibiotic
Marine Drugs, 2013 , vo...
Title/Abstract Full Text View citing articles Show Details
Desbois, Andrew P.; Lawlor, Keelan C.
Marine Drugs, 2013 , vol. 11, # 11 p. 4544 - 4557 Title/Abstract Full Text View citing articles Show Details
1
MBC
>
4096
mg/L
Desbois, Andrew P.; Lawlor, Keelan C.
Marine Drugs, 2013 , vol. 11, # 11 p. 4544 - 4557 Title/Abstract Full Text View citing articles Show Details
2.68
MIC
512
mg/L
Desbois, Andrew P.; Lawlor, Keelan C.
Marine Drugs, 2013 , vol. 11, # 11 p. 4544 - 4557 Title/Abstract Full Text View citing articles Show Details
2.68
MBC
512
mg/L
Desbois, Andrew P.; Lawlor, Keelan C.
Marine Drugs, 2013 , vol. 11, # 11 p. 4544 - 4557 Title/Abstract Full Text View citing articles Show Details
Identification Physical Data Spectra Other Data